{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:54:19Z","timestamp":1773964459934,"version":"3.50.1"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n            <jats:title>Summary:<\/jats:title>\n            <jats:p>Pain is an unpleasant experience resulting from either tissue damage or insults to the somatosensory system. Approaches to pain management evolve as we better understand both pain pathways and the tools available to interrupt these. The interest surrounding botulinum neurotoxin as a chemodenervating agent has expanded to include its potential applications in painful pathologies, both within and beyond the confines of plastic surgery. In this article, the authors discuss botulinum neurotoxin\u2019s mechanism of action as it pertains to both muscular paralysis and its interplay in the modulation of proinflammatory pain mediators. In addition, the authors review evidence supporting the use of botulinum neurotoxin in common painful conditions, in order to prepare the readership to aptly provide their patients with evidence-based recommendations. After reading this article, the participant should be able to discuss both mechanism of action and common applications of botulinum neurotoxin in painful conditions.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/prs.0000000000006559","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T21:23:32Z","timestamp":1582665812000},"page":"629e-636e","source":"Crossref","is-referenced-by-count":17,"title":["The Use of Botulinum Toxin in Pain Management: Basic Science and Clinical Applications"],"prefix":"10.1097","volume":"145","author":[{"given":"Jason D.","family":"Hehr","sequence":"first","affiliation":[{"name":"From the Department of Plastic and Reconstructive Surgery, Ohio State University Wexner Medical Center."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna R.","family":"Schoenbrunner","sequence":"additional","affiliation":[{"name":"From the Department of Plastic and Reconstructive Surgery, Ohio State University Wexner Medical Center."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E","family":"Janis","sequence":"additional","affiliation":[{"name":"From the Department of Plastic and Reconstructive Surgery, Ohio State University Wexner Medical Center."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"5 Suppl","key":"R4-20231017","doi-asserted-by":"crossref","first-page":"104S","DOI":"10.1097\/PRS.0000000000001732","article-title":"Neurotoxins: expanding uses of neuromodulators in medicine\u2014Headache.","volume":"136","author":"Nahabet","year":"2015","journal-title":"Plast Reconstr Surg"},{"issue":"5 Suppl","key":"R5-20231017","doi-asserted-by":"crossref","first-page":"177S","DOI":"10.1097\/01.PRS.0000082208.37239.5B","article-title":"The cosmetic use of botulinum toxin.","volume":"112","author":"Rohrich","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"R6-20231017","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: Genetic, structural and mechanistic insights.","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"R7-20231017","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pain.2003.10.008","article-title":"Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.","volume":"107","author":"Cui","year":"2004","journal-title":"Pain"},{"key":"R8-20231017","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology.","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"key":"R9-20231017","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.","volume":"67","author":"Naumann","year":"2013","journal-title":"Toxicon"},{"issue":"2 Pt A","key":"R10-20231017","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jmb.2015.10.024","article-title":"Identification and characterization of botulinum neurotoxin A substrate binding pockets and their re-engineering for human SNAP-23.","volume":"428","author":"Sikorra","year":"2016","journal-title":"J Mol Biol"},{"key":"R11-20231017","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3390\/toxins7083127","article-title":"Botulinum toxin for neuropathic pain: A review of the literature.","volume":"7","author":"Oh","year":"2015","journal-title":"Toxins (Basel)"},{"issue":"Pt 16","key":"R12-20231017","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","article-title":"Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential.","volume":"120","author":"Meng","year":"2007","journal-title":"J Cell Sci"},{"key":"R13-20231017","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.urology.2007.12.057","article-title":"Vesicovaginal fistula repair with rectus abdominus myofascial interposition flap.","volume":"71","author":"Reynolds","year":"2008","journal-title":"Urology"},{"key":"R14-20231017","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/apm.12458","article-title":"Systemic Epstein-Barr virus-negative mature natural killer-cell lymphoma with cutaneous and visceral involvement.","volume":"123","author":"Kim","year":"2015","journal-title":"APMIS"},{"key":"R15-20231017","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.juro.2007.07.120","article-title":"Intraprostatic botulinum toxin A injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat.","volume":"180","author":"Chuang","year":"2008","journal-title":"J Urol"},{"key":"R16-20231017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1254\/jphs.11060FP","article-title":"Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons.","volume":"118","author":"Shin","year":"2012","journal-title":"J Pharmacol Sci"},{"issue":"1 Suppl 1","key":"R17-20231017","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jpain.2005.09.006","article-title":"Sodium channels and mechanisms of neuropathic pain.","volume":"7","author":"Devor","year":"2006","journal-title":"J Pain"},{"key":"R18-20231017","doi-asserted-by":"crossref","first-page":"15650","DOI":"10.1523\/JNEUROSCI.2618-11.2011","article-title":"Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT\/A).","volume":"31","author":"Restani","year":"2011","journal-title":"J Neurosci"},{"key":"R19-20231017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.neuroscience.2011.04.026","article-title":"Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A.","volume":"186","author":"Matak","year":"2011","journal-title":"Neuroscience"},{"key":"R20-20231017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.toxicon.2017.05.001","article-title":"Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain.","volume":"133","author":"Fan","year":"2017","journal-title":"Toxicon"},{"key":"R21-20231017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pneurobio.2014.06.001","article-title":"Botulinum toxin A, brain and pain.","volume":"119-120","author":"Matak","year":"2014","journal-title":"Prog Neurobiol"},{"key":"R22-20231017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1073858414524633","article-title":"More than at the neuromuscular synapse: Actions of botulinum neurotoxin A in the central nervous system.","volume":"21","author":"Mazzocchio","year":"2015","journal-title":"Neuroscientist"},{"key":"R23-20231017","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.3390\/toxins7114519","article-title":"Current status and future directions of botulinum neurotoxins for targeting pain processing.","volume":"7","author":"Pellett","year":"2015","journal-title":"Toxins (Basel)"},{"key":"R24-20231017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00006534-199407000-00009","article-title":"Botulinum toxin A for hyperkinetic facial lines: Results of a double-blind, placebo-controlled study.","volume":"94","author":"Keen","year":"1994","journal-title":"Plast Reconstr Surg"},{"key":"R25-20231017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1526-4610.2005.05066.x","article-title":"Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial.","volume":"45","author":"Mathew","year":"2005","journal-title":"Headache"},{"key":"R26-20231017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1526-4610.2005.05068.x","article-title":"Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study.","volume":"45","author":"Dodick","year":"2005","journal-title":"Headache"},{"key":"R27-20231017","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program.","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"R28-20231017","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/PRS.0b013e3181f95a01","article-title":"Migraine surgery: A plastic surgery solution for refractory migraine headache.","volume":"127","author":"Kung","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R29-20231017","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/PRS.0000000000001572","article-title":"The current means for detection of migraine headache trigger sites.","volume":"136","author":"Guyuron","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"R30-20231017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1468-2982.23.s1.1.x","article-title":"Peripheral and central activation of trigeminal pain pathways in migraine: Data from experimental animal models.","volume":"23","author":"Buzzi","year":"2003","journal-title":"Cephalalgia"},{"key":"R31-20231017","doi-asserted-by":"crossref","first-page":"e1270","DOI":"10.1097\/GOX.0000000000001270","article-title":"Targeted peripheral nerve-directed onabotulinumtoxin A injection for effective long-term therapy for migraine headache.","volume":"5","author":"Janis","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"R32-20231017","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2362.2004.01324.x","article-title":"Botulinum toxin in the treatment of Raynaud\u2019s phenomenon: A pilot study.","volume":"34","author":"Sycha","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R33-20231017","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hcl.2014.09.003","article-title":"The role of botulinum toxin in vasospastic disorders of the hand.","volume":"31","author":"Neumeister","year":"2015","journal-title":"Hand Clin"},{"issue":"6 Suppl","key":"R34-20231017","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/00002508-200211001-00002","article-title":"Therapeutic use of botulinum toxins: Background and history.","volume":"18","author":"Setler","year":"2002","journal-title":"Clin J Pain"},{"key":"R35-20231017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2146\/ajhp050137","article-title":"Unlabeled uses of botulinum toxins: A review, Part 1.","volume":"63","author":"Cheng","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"R36-20231017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/157016109787354105","article-title":"Neuronal regulators and vascular dysfunction in Raynaud\u2019s phenomenon and systemic sclerosis.","volume":"7","author":"Fonseca","year":"2009","journal-title":"Curr Vasc Pharmacol"},{"key":"R37-20231017","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1346-8138.13030","article-title":"Beneficial effect of botulinum toxin A on Raynaud\u2019s phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.","volume":"43","author":"Motegi","year":"2016","journal-title":"J Dermatol"},{"key":"R38-20231017","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.jhsa.2010.09.019","article-title":"Botulinum toxin type A in the treatment of Raynaud\u2019s phenomenon.","volume":"35","author":"Neumeister","year":"2010","journal-title":"J Hand Surg Am"},{"key":"R39-20231017","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PRS.0b013e3181a80576","article-title":"Botox therapy for ischemic digits.","volume":"124","author":"Neumeister","year":"2009","journal-title":"Plast Reconstr Surg"},{"key":"R40-20231017","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhsa.2008.11.026","article-title":"Botulinum toxin type A: A treatment option for digital ischemia in patients with Raynaud\u2019s phenomenon.","volume":"34","author":"Fregene","year":"2009","journal-title":"J Hand Surg Am"},{"key":"R41-20231017","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00268-013-2211-6","article-title":"Outcomes of chemical component paralysis using botulinum toxin for incisional hernia repairs.","volume":"37","author":"Zendejas","year":"2013","journal-title":"World J Surg"},{"key":"R42-20231017","first-page":"121","article-title":"Postamputation pain: Epidemiology, mechanisms, and treatment.","volume":"6","author":"Hsu","year":"2013","journal-title":"J Pain Res"},{"key":"R43-20231017","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1526-4637.2008.00554.x","article-title":"Treatment of phantom limb pain with botulinum toxin type A.","volume":"10","author":"Jin","year":"2009","journal-title":"Pain Med"},{"key":"R44-20231017","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/AJP.0b013e3182264fe9","article-title":"A prospective randomized double-blinded pilot study to examine the effect of botulinum toxin type A injection versus lidocaine\/Depomedrol injection on residual and phantom limb pain: Initial report.","volume":"28","author":"Wu","year":"2012","journal-title":"Clin J Pain"},{"key":"R45-20231017","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1129-2377-14-92","article-title":"Botulinum toxin-type A: Could it be an effective treatment option in intractable trigeminal neuralgia?","volume":"14","author":"Shehata","year":"2013","journal-title":"J Headache Pain"},{"key":"R46-20231017","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/00207454.2015.1019624","article-title":"Botulinum toxin A in the treatment of trigeminal neuralgia.","volume":"126","author":"Xia","year":"2016","journal-title":"Int J Neurosci"},{"key":"R47-20231017","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1129-2377-15-65","article-title":"Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial.","volume":"15","author":"Zhang","year":"2014","journal-title":"J Headache Pain"},{"key":"R48-20231017","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.2147\/JPR.S168650","article-title":"Botulinum toxin-A for the treatment of neuralgia: A systematic review and meta-analysis.","volume":"11","author":"Meng","year":"2018","journal-title":"J Pain Res"},{"key":"R49-20231017","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/j.1526-4637.2010.01003.x","article-title":"Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia.","volume":"11","author":"Xiao","year":"2010","journal-title":"Pain Med"},{"key":"R50-20231017","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/AJP.0b013e31827a72d2","article-title":"Botulinum toxin A in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo-controlled trial.","volume":"29","author":"Apalla","year":"2013","journal-title":"Clin J Pain"},{"key":"R51-20231017","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1212\/WNL.0000000000003882","article-title":"Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review.","volume":"88","author":"Waldfogel","year":"2017","journal-title":"Neurology"},{"key":"R52-20231017","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/01.wnl.0000345968.05959.cf","article-title":"Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial.","volume":"72","author":"Yuan","year":"2009","journal-title":"Neurology"},{"key":"R53-20231017","first-page":"106","article-title":"The effects of intradermal botulinum toxin type A injections on pain symptoms of patients with diabetic neuropathy.","volume":"19","author":"Ghasemi","year":"2014","journal-title":"J Res Med Sci"},{"key":"R54-20231017","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.12659\/MSM.897350","article-title":"Intravesical botulinum toxin A injections for bladder pain syndrome\/interstitial cystitis: A systematic review and meta-analysis of controlled studies.","volume":"22","author":"Wang","year":"2016","journal-title":"Med Sci Monit"},{"key":"R55-20231017","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/01.AOG.0000237100.29870.cc","article-title":"Botulinum toxin type A for chronic pain and pelvic floor spasm in women: A randomized controlled trial.","volume":"108","author":"Abbott","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R56-20231017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/SPV.0000000000000177","article-title":"Botulinum toxin A injections into pelvic floor muscles under electromyographic guidance for women with refractory high-tone pelvic floor dysfunction: A 6-month prospective pilot study.","volume":"21","author":"Morrissey","year":"2015","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"R57-20231017","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations.","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"}],"container-title":["Plastic &amp; Reconstructive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000006559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T22:10:47Z","timestamp":1697580647000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PRS.0000000000006559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/prs.0000000000006559","relation":{},"ISSN":["0032-1052"],"issn-type":[{"value":"0032-1052","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}